Denosumab Treatment in CKD Patients at High Risk of Fracture

The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.

Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.